These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37921523)

  • 1. Tear Tacrolimus Levels and Clinical Response After Adjunct Therapy With Cutaneous Application of Tacrolimus 0.1% Over Upper Eyelid Skin in Chronic Vernal Keratoconjunctivitis.
    Bardoloi P; Vanathi M; Velpandian T; Laxmi M; Gupta N; Lomi N; Tandon R
    Cornea; 2023 Nov; ():. PubMed ID: 37921523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of topical tacrolimus 0.03% in the management of vernal keratoconjunctivitis: a non-randomized controlled clinical trial.
    Eltagoury M; Abou Samra W; Ghoneim E
    Med Hypothesis Discov Innov Ophthalmol; 2022; 11(2):52-63. PubMed ID: 37641784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis.
    Nivenius E; van der Ploeg I; Jung K; Chryssanthou E; van Hage M; Montan PG
    Eye (Lond); 2007 Jul; 21(7):968-75. PubMed ID: 16680103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis.
    Liu FY; Liu HY; Chu HS; Chen WL; Hu FR; Wang IJ
    Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):967-974. PubMed ID: 30852635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis.
    Wan Q; Tang J; Han Y; Wang D; Ye H
    Ophthalmic Res; 2018; 59(3):126-134. PubMed ID: 28803239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effect of 0.1% Tacrolimus Eye Ointment in Allergic Ocular Diseases.
    Barot RK; Shitole SC; Bhagat N; Patil D; Sawant P; Patil K
    J Clin Diagn Res; 2016 Jun; 10(6):NC05-9. PubMed ID: 27504320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Clinical Outcome of Tacrolimus Skin Ointment (0.03%) for the Treatment of Vernal Keratoconjunctivitis: A Quasi-Experimental Study.
    Ali W; Alam Khan S; Ullah Khan F; Khan S; Khan WA; Zafar R; Moqeet MA
    Cureus; 2023 Dec; 15(12):e50579. PubMed ID: 38226116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating refractory corneal hydrops in a male patient with vernal keratoconjunctivitis and mental retardation: a case report.
    Shih EJ; Lin JC; Peng KL; Chen JL
    BMC Ophthalmol; 2022 Jan; 22(1):36. PubMed ID: 35073856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis.
    Al-Amri AM; Mirza AG; Al-Hakami AM
    Middle East Afr J Ophthalmol; 2016; 23(1):135-8. PubMed ID: 26957853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When to start tacrolimus ointment for vernal keratoconjunctivitis? A proposed treatment protocol.
    Arnon R; Rozen-Knisbacher I; Yahalomi T; Stanescu N; Niazov Y; Goldberg D; Sharabi-Nov A; Mostovoy D
    Int Ophthalmol; 2022 Jun; 42(6):1771-1780. PubMed ID: 34981294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with vernal keratoconjunctivitis.
    Saha BC; Kumari R; Ambasta A
    Ther Adv Ophthalmol; 2023; 15():25158414231173532. PubMed ID: 37255622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis.
    Shoughy SS; Jaroudi MO; Tabbara KF
    Clin Ophthalmol; 2016; 10():643-7. PubMed ID: 27103784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes.
    Vichyanond P; Pacharn P; Pleyer U; Leonardi A
    Pediatr Allergy Immunol; 2014 Jun; 25(4):314-22. PubMed ID: 24438133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Follow-up study on patients with vernal keratoconjunctivitis undergoing topical 0.1% tacrolimus treatment].
    Harada N; Inada N; Ishimori A; Shoji J; Sawa M
    Nippon Ganka Gakkai Zasshi; 2014 Apr; 118(4):378-84. PubMed ID: 24864437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of 0.05% Azelastine and 0.1% Tacrolimus Eye Drops in Children With Vernal Keratoconjunctivitis: A Prospective Study.
    Chen M; Wei A; Ke B; Zou J; Gong L; Wang Y; Zhang C; Xu J; Yin J; Hong J
    Front Med (Lausanne); 2021; 8():650083. PubMed ID: 34604246
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of 2% Rebamipide Suspension for Vernal Keratoconjunctivitis: A Clinical Comparison with Topical Immune Modulators Cyclosporine and Tacrolimus.
    Malhotra C; Singh H; Jain AK; Gupta A; Ram J
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1083-1091. PubMed ID: 33764241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre.
    Gupta S; Singh P; Singh M; Naik M; Srivastava K
    Clin Ophthalmol; 2021; 15():2993-2999. PubMed ID: 34285466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis.
    Chatterjee S; Agrawal D
    Cornea; 2016 Nov; 35(11):1444-1448. PubMed ID: 27310883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular surface characteristics in pediatric vernal keratoconjunctivitis: a clinico-cytological study.
    Sabu S; Gupta N; Raj N; Panigrahi A; Lomi N; Vanathi M; Vashist P; Sen S; Tandon R
    J AAPOS; 2022 Oct; 26(5):240.e1-240.e6. PubMed ID: 36122877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of topical 0.03% Tacrolimus ointment in children with refractory vernal keratoconjunctivitis in Middle East.
    Fiorentini SF; Khurram D
    Saudi J Ophthalmol; 2019; 33(2):117-120. PubMed ID: 31384152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.